Recent Updates
Recently added Catalysts

CVL-231 as IR formulation

Phase 1

Schizophrenia | Small molecule | Psychiatry |AbbVie Inc.|Last Updated: Apr 26, 2022

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment16

FDA Designations

No designations recorded

Clinical trial landscape

CVL-231 as IR formulation · 1 trial · 1 indication

Phase 1 1
NCT05106309Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy ParticipantsSchizophrenia
COMPLETED16 Analytics
PHASE1COMPLETED
Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants
Schizophrenia
NCT0510630916
Unlock trial analytics

Study Design & Arms

Interventions

NameTypeDescription
10 mg CVL-231 as IR formulationDRUGTablets
30 mg CVL-231 as slow-release MR formulationDRUGCapsules
30 mg CVL-231 as medium release MR formulationDRUGCapsules
30 mg CVL-231 as fast release MR formulationDRUGCapsules
30 mg CVL-231 Target Release, FastedDRUGCapsules
30 mg CVL-231 Target Release, FedDRUGCapsules
Unlock Study Design Details

Competitive Landscape -Schizophrenia 36 trials

CompanyTickerTrialsLead PhaseDrugs
Neurocrine Biosciences, Inc.NBIX5PHASE3NBI-1117568
Bristol-Myers Squibb CompanyBMY8PHASE3KarXT
LB Pharmaceuticals, Inc.LBRX2PHASE3LB-102
Alkermes Public Limited CompanyALKS2PHASE3OLZ/SAM
Vanda Pharmaceuticals Inc.VNDA1PHASE3iloperidone
Eli Lilly and CompanyLLY2PHASE2Brenipatide
Novartis AG Sponsored ADRNVS1PHASE2GXV813
Reviva Pharmaceuticals Holdings, Inc.RVPH1PHASE3Brilaroxazine
AbbVie, Inc.ABBV1PHASE2Emraclidine
Alto Neuroscience, Inc.ANRO1PHASE2ALTO-101
Anavex Life Sciences Corp.AVXL1PHASE2ANAVEX3-71
Minerva Neurosciences IncNERV1PHASE3Roluperidone, risperidone, aripiprazole, olanzapine
MapLight Therapeutics, Inc.MPLT1PHASE2ML-007C-MA
BioXcel Therapeutics, Inc.BTAI1PHASE1BXCL501 80 Micrograms, BXCL501 120 Micrograms, BXCL501 60 Micrograms
Unlock Competitive Intelligence

Frequently asked questions about CVL-231 as IR formulation

What is CVL-231 as IR formulation used for?

CVL-231 as IR formulation is an investigational small molecule being developed for the treatment of schizophrenia. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.

Who makes CVL-231 as IR formulation?

CVL-231 as IR formulation is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol ABBV.

What phase is CVL-231 as IR formulation in?

CVL-231 as IR formulation is in Phase 1 clinical development. It is an investigational drug and has not been approved for any use. One Phase 1 trial has been completed.

What clinical trials is CVL-231 as IR formulation in?

CVL-231 as IR formulation has one completed clinical trial, NCT05106309, which studied the pharmacokinetics of the drug following single oral administration of modified- and immediate-release formulations in fasted and fed healthy participants.

Is CVL-231 as IR formulation the same as CVL-231?

CVL-231 as IR formulation refers to the immediate-release version of the drug CVL-231. The clinical trial NCT05106309 evaluated both modified- and immediate-release formulations of CVL-231.